N/A
N=124
Ambispective, Multicentre, Open-label Study Evaluating the Clinical Outcomes of Foot Surgery Using SERF Medical Devices
Foot Diseases
Bottom Line
View on ClinicalTrials.gov: NCT05672069 ↗Enrolled (actual)
124
Serious AEs
4.1%
Results posted
Jan 2025
Primary outcome: Primary: Reduction of the Patient's Pain and Restoration of Walking — 42.46; 88.44 points
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Osteosynthesis (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Societe dEtude, de Recherche et de Fabrication
- Primary completion
- Dec 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Reduction of the Patient's Pain and Restoration of Walking |
42.46; 88.44 | — |
| SECONDARY Survival Rate |
89.3 | — |
| SECONDARY Foot Bone Consolidation |
124; 2; 1; 7 | — |
| SECONDARY Patient Satisfaction |
103; 20; 6; 5 | — |
| SECONDARY Adverse Event |
8; 3; 2; 2; 1; 1 | — |
Summary
This clinical investigation was led as a post-marketing clinical follow-up study conducted as part of standard care with an additional, non-invasive, non-invasive procedure (Case 4.1) ambispective, multicentre, open-label, non-comparative.
The primary objective of this study is to evaluate the reduction in patient pain and the restoration of walking. The study will also collect performance and safety data to assess the subject's outcomes and functional status.
The target population for this study was any adult patient implanted with FAST screws, FAST plates, Toe FAST and VEOFIX screws between november 2021 and october 2022.
The investigation will be conducted in accordance with the investigation protocol, the laws and regulations (including the Medical regulations (including the Medical Devices Regulation 2017/745) and the ISO 14155:2020, as well as in accordance with the ethical principles described in the Declaration of Helsinki. The collection of personal data will also be compliant with RGPD 2016/679.
Eligibility Criteria
Inclusion Criteria
- Male or female subject of legal age at the date of implantation;
- Subject implanted with one or more implants: FAST Screw, FAST Plate, Toe FAST and VEOFIX Screw between November 2021 and October 2022;
- Subject able to understand the information and instructions given by the investigator;
- Subject with a social security affiliation.
Exclusion Criteria
- Vulnerable persons
- People with contraindications (including pregnant women)
Data sourced from ClinicalTrials.gov (NCT05672069). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.